# US 2006/0154238 A1 · Compounds and methods of early diagnosis of cervical cancer and genital condyloma with hpv, chsp60 tumor suppressor h-ras, k-ras and pten derived peptides modified

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154238 A1
- Document ID: US20060154238A1
- Status: Published application
- Kind: A1
- Application number: 10/905,527
- Filed: 2005-01-07
- Published: 2006-07-13
- Earliest claimed: 2005-01-07
- Inventors: Yao-Xiong Hu
- Web page: https://patentgrep.com/patent/US20060154238A1

## CPC

- C07K 14/005: from viruses
- G01N 33/5755: of the uterine cervix, uterine corpus or endometrium
- C07K 2319/00: Fusion polypeptide
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An isolated sequence or peptide isolated from an E2, E4, E6, E7 early or late coding region of human papillomavirus (HPV) that is soluble in aqueous medium, and characterized by a linkage to another protein sequence or peptide isolated from the E2, E4, E6, E7 early or late coding region of HPV by a spacer sequence, wherein the isolated protein sequence or peptide consists of more than 50% hydrophilic amino acids, and is recognized by a specific antibody of HPV. Also disclosed are isolated protein sequences or peptides from Harvey Ras (H-Ras), Kirsten Ras (K-Ras), and phosphatase and tensin homologue (PTEN) tumor suppressor proteins and Chlamydia trachomatis heat shock protein 60 (CHSP60 groEL1) and methods for detecting or diagnosing cancer or cellular abnormalities.

## Claims

### Claim 1

An protein sequence or peptide isolated from an E2, E4, E6, E7 early or late coding region of human papillomavirus (HPV) that is soluble in aqueous medium, and characterized by a linkage to another protein sequence or peptide isolated from the E2, E4, E6, E7 early or late coding region of HPV by a spacer sequence, wherein the isolated protein sequence or peptide consists of more than 50% hydrophilic amino acids, and is recognized by a specific antibody of HPV.

### Claim 2 (depends on 1)

The isolated protein sequence or peptide of claim 1, wherein the HPV is selected from the group consisting of 6, 11, 16, 18 31, 33, 45, 52 and 58.

### Claim 3 (depends on 1)

The isolated protein sequence or peptide of claim 1, wherein the spacer sequence comprises a plurality of neutral, genetically coded amino acid residues.

### Claim 4 (depends on 1)

An isolated protein sequence or peptide of claim 1, further comprising an additional polar residue to the amino terminal residue of the isolated protein sequence or peptide, wherein the polar residue is selected from the group consisting of lysine, arginine, and histidine.

### Claim 5 (depends on 1)

An isolated protein sequence or peptide of claim 1, further comprising an additional negatively charged residue to the carboxyl terminal residue of the isolated protein sequence or peptide, wherein the negatively charged residue is selected from the group consisting of aspartic acid, glutamic acid, and tyrosine.

### Claim 6

An isolated protein sequence or peptide from HPV for detecting or diagnosing cancer or cellular abnormalities, said isolated protein sequence or peptide selected from the group consisting of:
an E2 region of HPV 18 and an L1 region of HPV 16 and HPV 18 as set forth in SEQ. ID. NO.: 9;
an E7 region of HPV 16 and an L1 region of HPV 16 and HPV 18 as set forth in SEQ. ID. NO.: 11;
an E7 region of HPV 16 and HPV 18 as set forth in SEQ. ID. NO.: 12;
an L1 region of HPV 16 and HPV 18 and an E7 region of HPV 58 as set forth in SEQ. ID. NO.: 14;
an E7 region of HPV 58 and HPV 16 as set forth in SEQ. ID. NO.: 15;
an E6 region of HPV 58 and an E7 region of HPV 16 as set forth in SEQ. ID. No.: 16;
an E6 region of HPV 58 and HPV 16 as set forth in SEQ. ID. No.: 17;
an E7 region of HPV 16 and an E6 region of HPV 58 as set forth in SEQ. ID. No.: 18;
an E6 region of HPV 58 and an E7 region of HPV 16 as set forth in SEQ. ID. No.: 19;
an E7 region of HPV 16 and an E6 region of HPV 58 and HPV 16 as set forth in SEQ. ID. No.: 20;
an E6 region of HPV 16 and HPV 52 and an E7 region of HPV 58 as set forth in SEQ. ID. No.: 22;
an E7 region of HPV 16 and HPV 58 as set forth in SEQ. ID. No.: 23;
an E6 region of HPV 16 and HPV 52 as set forth in SEQ. ID. No.: 24;
an E6 region of HPV 52 and an E7 region of HPV 58 as set forth in SEQ. ID. No.: 25;
an E7 region of HPV 58 and HPV 52 as set forth in SEQ. ID. No.: 28;
an E6 and E2 region of HPV 16 as set forth in SEQ. ID. No.: 29;
an E7 region of HPV 16 as set forth in SEQ. ID. No.: 30; and
an E7 and E2 region of HPV 18 as set forth in SEQ. ID. No.: 43.

### Claim 7

An protein sequence or peptide isolated from a Harvey Ras (H-Ras) tumor suppressor protein that is soluble in aqueous medium, and characterized by a linkage to another protein sequence or peptide isolated from an E2, E4 early or late coding region of HPV by a spacer sequence, wherein the isolated protein sequence or peptide consists of more than 50% hydrophilic amino acids, and is recognized by a specific antibody of HPV.

### Claim 8 (depends on 7)

The isolated protein sequence or peptide of claim 7, wherein the HPV is selected from the group consisting of 16, 31, 33, 45, and 58.

### Claim 9 (depends on 7)

The isolated protein sequence or peptide of claim 7, wherein the spacer sequence comprises a plurality of neutral, genetically coded amino acid residues.

### Claim 10

An isolated protein sequence or peptide from H-Ras characterized by a linkage to another isolated protein sequence from HPV for detecting or diagnosing cancer or cellular abnormalities, said isolated protein sequence or peptide selected from the group consisting of:
a region of H-Ras and an E4 region of HPV 16 as set forth in SEQ. ID. NO.: 154;
a region of H-Ras and an E4 region of HPV 33 as set forth in SEQ. ID. NO.: 155;
a region of H-Ras and an E4 region of HPV 33 as set forth in SEQ. ID. NO.: 156; and
a region of H-Ras and an E4 region of HPV 33 as set forth in SEQ. ID. NO.: 157.

### Claim 11

An protein sequence or peptide isolated from a Kirsten Ras (K-Ras) tumor suppressor protein that is soluble in aqueous medium, and characterized by a linkage to another protein sequence or peptide isolated from an E2, E4, E5 early or late coding region of HPV by a spacer sequence, wherein the isolated protein sequence or peptide consists of more than 50% hydrophilic amino acids, and is recognized by a specific antibody of HPV.

### Claim 12 (depends on 11)

The isolated protein sequence or peptide of claim 11, wherein the HPV is selected from the group consisting of 16 and 18.

### Claim 13 (depends on 11)

The isolated protein sequence or peptide of claim 11, wherein the spacer sequence comprises a plurality of neutral, genetically coded amino acid residues.

### Claim 14

An isolated protein sequence or peptide from K-Ras characterized by a linkage to another isolated protein sequence from HPV for detecting or diagnosing cancer or cellular abnormalities, said isolated protein sequence or peptide selected from the group consisting of:
a region of K-Ras and an E2 region of HPV 16 as set forth in SEQ. ID. NO.: 165; and
a region of K-Ras and an E5 region of HPV 16 as set forth in SEQ. ID. NO.: 167.

### Claim 15

An protein sequence or peptide isolated from a Phosphatase and tensin homologue (PTEN) tumor suppressor protein that is soluble in aqueous medium, and characterized by a linkage to another protein sequence or peptide isolated from the PTEN protein by a spacer sequence, wherein the isolated protein sequence or peptide consists of more than 50% hydrophilic amino acids, and is recognized by a specific antibody of PTEN.

### Claim 16 (depends on 15)

The isolated protein sequence or peptide of claim 15, wherein the spacer sequence comprises a plurality of neutral, genetically coded amino acid residues.

### Claim 17

An isolated protein sequence or peptide from PTEN for detecting or diagnosing cancer or cellular abnormalities, said isolated protein sequence or peptide selected from the group consisting of:
a region of PTEN as set forth in SEQ. ID. NO.: 174;
a region of PTEN as set forth in SEQ. ID. NO.: 175; and
a region of PTEN as set forth in SEQ. ID. NO.: 176.

### Claim 18

An protein sequence or peptide isolated from a Chlamydia trachomatis heat shock protein 60 (CHSP60 groEL1) that is soluble in aqueous medium, and characterized by a linkage to another protein sequence or peptide isolated from the E6, E7 early or late coding region of HPV by a spacer sequence, wherein the isolated protein sequence or peptide consists of more than 50% hydrophilic amino acids, and is recognized by a specific antibody of HPV.

### Claim 19 (depends on 18)

The isolated protein sequence or peptide of claim 18, wherein the HPV is selected from the group consisting of 16, 18, and 58.

### Claim 20 (depends on 18)

The isolated protein sequence or peptide of claim 18, wherein the spacer sequence comprises a plurality of neutral, genetically coded amino acid residues.

### Claim 21

An isolated protein sequence or peptide from CHSP60 for detecting or diagnosing cancer or cellular abnormalities, said isolated protein sequence or peptide selected from the group consisting of:
a region of CHSP60 as set forth in SEQ. ID. NO.: 170;
a region of CHSP60 as set forth in SEQ. ID. NO.: 171; and
a region of CHSP60 as set forth in SEQ. ID. NO.: 172.

### Claim 22

An isolated protein sequence or peptide from CHSP60 characterized by a linkage to another isolated protein sequence from HPV for detecting or diagnosing cancer or cellular abnormalities, said isolated protein sequence or peptide selected from the group consisting of:
a region of CHSP60 and an E7 region of HPV 16 as set forth in SEQ. ID. NO.: 178; and
a region of CHSP60 protein and an E6 region of HPV 16 as set forth in SEQ. ID. NO.: 179.

### Claim 23

A method for detecting or diagnosing cancer or cellular abnormalities, said method comprising the steps of:
reacting a sample of body fluid or tissue likely to contain antibodies to one or more protein sequences or peptides isolated from the E2, E4, E6, E7 early or late coding region of human papillomavirus (HPV), and characterized by a linkage to another protein sequence or peptide isolated from the E2, E4, E6, E7 early or late coding regions of HPV by a spacer sequence, wherein the isolated protein sequence or peptide consists of more than 50% hydrophilic amino acids, and is recognized by a specific antibody of HPV;
forming an antibody-peptide complex comprising at least one of the isolated protein sequences or peptides and the sample antibodies; and
detecting the antibody-peptide complex.

### Claim 24 (depends on 23)

The method for detecting or diagnosing cancer or cellular abnormalities as defined in claim 23, wherein the HPV is selected from the group consisting of 6, 11, 16, 18 31, 33, 45, 52 and 58.

### Claim 25 (depends on 23)

The isolated protein sequence or peptide of claim 23, wherein the spacer sequence comprises a plurality of neutral, genetically coded amino acid residues.

### Claim 26 (depends on 23)

The method for detecting or diagnosing cancer or cellular abnormalities of claim 23, wherein said diagnostic method is directed to detecting or diagnosing an HPV associated precancerous or premalignant condition.

### Claim 27 (depends on 23)

The method for detecting or diagnosing cancer or cellular abnormalities of claim 23, wherein said diagnostic method is directed to detecting or diagnosing an HPV associated cancer.

### Claim 28 (depends on 23)

The method for detecting or diagnosing cancer or cellular abnormalities as defined in claim 23, wherein the detection step further comprises visually inspecting the antibody-peptide complex for a color change.

### Claim 29 (depends on 23)

The method for detecting or diagnosing cancer or cellular abnormalities as defined in claim 23, wherein the detection step further comprises inspecting the antibody-peptide complex for physical-chemical changes.

### Claim 30 (depends on 29)

The method for detecting or diagnosing cancer or cellular abnormalities as defined in claim 29, wherein the inspection step further comprises inspecting the antibody-peptide complex using a spectrophotometer.
